Molecular genetics of bladder cancer: Pathways of development and progression

Cancer Surveys

Volumn 31, Issue , 1998, Pages 49-76

  Knowles, Margaret A ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER CANCER; DNA REPAIR; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCHISTOSOMIASIS; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; GENES, P16; GENES, P53; GENES, RAS; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; SCHISTOSOMIASIS; URINARY BLADDER NEOPLASMS;

EID: 0031807809     PISSN: 02612429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Bell D, Taylor JA, Paulson DF, Robertson CN, Mohler JL and Lucier GW (1993) Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. Journal of the National Cancer Institute 85 1159-1164
2. Bell SM, Zuo J, Myers RM and Knowles MA (1996) Fluorescence in situ hybridization deletion mapping at 4p 16.3 in bladder cancer cell lines refines the localization of the critical interval to 30kb. Genes, Chromosomes and Cancer 17 108-117
3. Bell SM, Shaw M, Jou Y-S, Myers KM and Knowles MA (1997) Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p l6.3 involved in bladder cancer. Genomics (in press)
4. Bergerheim USR, Kunimi K, Collins VP and Ekman P (1991) Deletion mapping on chromosomes 8, 10 and 16 in human prostatic carcinoma. Genes, Chromosomes and Cancer 3 215-220
5. Brewster SF, Gingell JC, Browne S and Brown KW (1994) Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder. British Journal of Cancer 70 697-700
6. Bringuier PP, Tamimi J and Schuuring E (1994) Amplification of the chromosome 11q13 region in bladder tumours. Urological Research 21 451
7. Bringuier PP, Tamimi Y, Schuuring E and Schalken J (1996) Expression of cyclin D1 and EMS1 in bladder tumours: relationship with chromosome 11q13 amplification. Oncogene 12 1747-1753
8. Brockmoller J, Kerb R, Drakoulis N, Staffeldt B and Roots I (1995) Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Research 54 4103-4111
9. Cairns P, Proctor AJ and Knowles MA (1991) Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 6 2305-2309
10. Cairns P, Shaw ME and Knowles MA (1993a) Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8 1083-1085
11. Cairns P, Shaw ME and Knowles MA (1993b) Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Research 53 1230-1232
12. Cairns P, Tokino K, Eby Y and Sidransky D (1994) Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Research 54 1422-1424
13. Cairns P, Polascik TJ, Eby Y et al (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genetics 11 210-212
14. Carbonara C, Longa L, Grosso E et al (1994) 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene. Human Molecular Genetics 3 1829-1832
15. Cartwright RA, Glashan RW, Rogers HJ et al (1982) The role of N-acetyltransferase in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet ii 842-846
16. Chang WY-H, Cairns P, Schoenberg MP, Polascik TJ and Sidransky D (1995) Novel suppressor loci on chromosome 14q in primary bladder cancer. Cancer Research 55 3246-3249
17. Chaturvedi V, Li L, Hodges S et al (1997) Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene 14 2059-2070
18. Cook PJ, Doll R and Fellingham S (1969) A mathematical model for the age distribution of cancer in man. International Journal of Cancer 4 93-112
19. Coombs LM, Piggott DA, Sweeney E et al (1991) Amplification and overexpression of c-erhB-2 in transitional cell carcinoma of the urinary bladder. British Journal of Cancer 63 601-608
20. Cordon-Cardo C, Wartinger D, Petrylak D et al (1992) Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. Journal of the National Cancer Institute 84 1251-1256
21. Cordon-Cardo C, Dalbagni G, Saez. GT et al (1994) TP53 mutations in human bladder cancer: genotypic versus phenotypic patterns. International Journal of Cancer 56 347-353
22. Cordon-Cardo C, Zhang Z-F, Dalbagni G et al (1997) Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Research 57 1217-1221
23. Cote RJ, Esrig D, Groshen S, Jones PA and Skinner DG (1997) p53 and treatment of bladder cancer, Nature 385 123-125
24. Dalbagni G, Presti J, Reuter V, Fair WR and Cordon-Cardo C (1993) Genetic alterations in bladder cancer. Lancet 342 469-471
25. Devlin J, Keen AJ and Knowles MA (1994) Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. Oncogene 9 2757-2760
26. Edwards PAW (1993) Tissue reconstitution models of breast cancer. In Lemoine NR and Wright NA (eds). Cancer Surveys vol. 16 Breast Cancer pp 79-96 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
27. El-Boukainy MN, Ghonein MA and Mansour MA (1972) Carcinoma of bilharzial bladder in Egypt: clinical and pathological features. British Journal of Urology 44 561-570
28. Elder PA, Bell SM and Knowles MA (1994) Deletion of two regions on chromosome 4 in bladder carcinoma: definition of a critical 750kb region at 4p16.3. Oncogene 9 3433-3436
29. Emi M, Fujiwara Y, Ohata H et al (1993) Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma. Genes, Chromosomes and Cancer 7 152-157
30. Emmert-Buck MR, Bonner RF, Smith PD et al (1996) Laser capture microdissection. Science 274 998-1001
31. Esrig D, Elmajian D, Groshen S et al (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. New England Journal of Medicine 331 1259-1264
32. Eydmann ME and Knowles MA (1997) Mutation analysis of 8p genes POLB and PPP2CB in bladder cancer. Cancer Genetics and Cytogenetics 93 167-171
33. Fearon ER, Feinberg AP, Hamilton SH and Vogelstein B (1985) Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 318 377-380
34. Fitzgerald JM, Ramchurren N, Rieger K et al (1995) Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. Journal of the National Cancer Institute 87 129-133
35. Fujimoto K, Yamada Y, Okajima E et al (1992) Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Research 52 1393-1398
36. Fujita J, Srivastava SK, Kraus MH, Rhim JS, Tronick SR and Aaronson SA (1985) Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. Proceedings of the National Academy of Sciences of the USA 82 3849-3853
37. Fujiwara Y, Emi M, Ohata H et al (1993) Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Research 53 1172-1174
38. Gonzalez-Zulueta M, Ruppert JM, Tokino K et al (1993) Microsatellite instability in bladder cancer. Cancer Research 53 5620-5623
39. Gonzalez-Zulueta M, Bender CM, Yang AS et al (1995a) Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Research 55 4531-4535
40. Gonzalez-Zulueta M, Shibata A, Ohneseit PF et al (1995b) High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. Journal of the National Cancer Institute 87 1383-1393
41. Green AJ, Johnson PH and Yates JRW (1994) The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Human Molecular Genetics 3 1833-1834
42. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Research 54 4855-4878
43. Gruis NA, Weaver-Feldhaus J, Liu Q et al (1995) Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. American Journal of Pathology 146 1199-1206
44. Habuchi T, Ogawa O, Kakehi Y et al (1993a) Accumulated allelic losses in the development of invasive urothelial cancer. International Journal of Cancer 53 579-584
45. Habuchi T, Takahashi R, Yamada H et al (1993b) Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Research 53 3795-3799
46. Habuchi T, Kinoshita H, Yamada H et al (1994) Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. Journal of the National Cancer Institute 86 1331-1335
47. Habuchi T, Devlin J, Elder PA and Knowles MA (1995) Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene 11 1671-1674
48. Habuchi T, Yoshida O and Knowles MA (1997) A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localisation of the candidate region within a single 840kb YAC. Human Molecular Genetics 6 913-919
49. Hussussian CJ, Struewing JP, Goldstein AM et al (1994) Germline mutations in familial melanoma. Nature Genetics 8 15-21
50. IARC (1994) Schistosomes, liver flukes and Helicobacter pylori. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 61
51. Ibrahim SA (1986) Site distribution of cancer in Egypt: twelve years' experience (1970-1981), In: Ismail A (ed.) Cancer Prevention in Developing Countries, pp. 45-50, Pergamon, Oxford
52. Ishikawa J, Xu H-J, Hu S-X et al (1991) Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Research 51 5736-5743
53. Kallioniemi A, Kallinniemi O-P, Sudar D et al (1992) Comparative genomic hybridization for molecular genetic analysis of solid tumors. Science 258 818-821
54. Kallioniemi A, Kallioniemi O-P, Citro G et al (1995) Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes, Chromosomes and Cancer 12 213-219
55. Kamb A, Gruis NA, Weaver-Feldhaus J et al (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264 436-440
56. Kantor AF, Hartge P, Hoover RN and Fraumeni JF Jr (1985) Familial and environmental interactions in bladder cancer risk. International Journal of Cancer 35 703-706
57. Keen AJ and Knowles MA (1994) Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9 2083-2088
58. Klingelhutz A, Wu S-Q, Bookland E and Reznikoff C (1991) Allelic 3p deletions in high grade carcinomas after transformation in vitro of human uroepithelial cells. Genes, Chromosomes and Cancer 3 346-357
59. Knowles MA, Shaw ME and Proctor AJ (1993) Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 8 1357-1364
60. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME and Law M (1994) Allelotype of human bladder cancer. Cancer Research 54 531-538
61. Koss LG (1975) Atlas of Tumor Pathology: Tumors of the Urinary Bladder (Fascicle 11), 2nd ed, Washington DC: Armed Forces Institute of Pathology
62. Koss LG (1979) Mapping of the urinary bladder: its impact on the concepts of bladder cancer. Human Pathology 10 533-548
63. Koss LG, Tiamson EM and Robbins MA (1974) Mapping cancerous and precancerous bladder changes. A study of the urothelium in ten surgically removed bladders. Journal of the American Medical Association 227 281-286
64. Koss LG, Nakanishi I and Freed SZ (1977) Nonpapillary carcinoma in situ and atypical hyper-plasia in cancerous bladders: further studies of surgically removed bladders by mapping. Urology 9 442-455
65. Lamm DL (1992) Carcinoma in situ. Urology Clinics of North America 19 499-508
66. Levesque P, Ramchuuren N, Saini K, Joyce A, Libertino J and Summerhayes IC (1993) Screening of human bladder tumors and urine sediments for the presence of H-ras mutations. International Journal of Cancer 55 785-790
67. Lianes P, Orlow I, Zhang Z-F et al (1994) Altered patterns of MDM2 and TP53 expression in human bladder cancer. Journal of the National Cancer Institute 86 1325-1330
68. Liang P and Pardee AB (1992) Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257 967-971
69. Lipponen PK (1993) Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. International Journal of Cancer 53 365-370
70. Lisitsyn N, Lisitsyn N and Wigler M (1993) Cloning the differences between complex genomes. Science 259 946-951
71. Logothetis CJ, Xu H-J, Ro JY et al (1992) Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer, Journal of the National Cancer Institute 84 1256-1261
72. Lowe SW, Ruley HE, Jacks T and Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 957-967
73. Lunec J, Challen C, Wright C, Mellon K and Neal DE (1992) c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder. Lancet 339 439-440
74. Lynch HT, Walzak MP, Fried R, Domina AH and Lynch JF (1979) Familial factors in bladder carcinoma. Journal of Urology 122 458-461
75. Lynch HT, Kimberling WJ, Lynch JF and Brennan K (1987) Familial bladder cancer in an oncology clinic. Cancer Genetics and Cytogenvtics 27 161-165
76. McCullough DL, Lamm DL, McLaughlin AP III and Gittes RF (1975) Familial transitional cell carcinoma of the bladder. Journal of Urology 113 629-639
77. Malone PR, Visvinathan KV, Ponder BAJ, Shearer RJ and Summerhayes IC (1985) Oncogenes and bladder cancer. British Journal of Urology 57 664-667
78. Mao L, Schoenberg MP, Scicchitano M et al (1996) Molecular detection of primary bladder cancer by microsatellite analysis. Science 271 659-662
79. Mellon JK, Lunec J, Wright C, Home CH, Kelly P and Neal DE (1996) C-ERBB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. Journal of Urology 155 321-326
80. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y and Kubota Y (1995) Retinoblastoma gene mutations in primary human bladder cancer. British Journal of Cancer 71 831-835
81. Miyao N, Tsai YC, Lerner SP et al (1993) Role of chromosome 9 in human bladder cancer. Cancer Research 53 4066-4070
82. Neal DE, Sharples L, Smith K, Fenelly J, Hall RH and Harris AL (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65 1619-1625
83. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368 753-756
84. Olumi AF, Tsai YC, Nichols PW et al (1990) Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Research 50 7081-7083
85. Ooi A, Herz F, Ii S et al (1994) Ha-ras codon 12 mutation in papillary tumors of the urinary bladder: a retrospective study. International Journal of Oncology 4 85-90
86. Orlow I, Lacombe L, Hannon GJ et al (1995) Deletion of the p16 and p15 genes in human bladder tumors. Journal of the National Cancer Institute 87 1524-1529
87. Perucho M (1997) Cancer of the microsatellite mutator phenotype. Biological Chemistry 11 675-684
88. Polascik TJ, Cairns P, Chang WYH, Schoenberg MP and Sidransky D (1995) Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Research 55 5396-5399
89. Pratt CI, Kao C, Wu S-Q, Gilchrist KW, Oyasu R and Reznikoff CA (1992) Neoplastic progression by EJ/ras at different steps of transformation in vitro of human uroepithelial cells. Cancer Research 52 688-695
90. Presti JC Jr, Reuter VE, Galan T, Fair WR and Cordon-Cardo C (1991) Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Research 51 5405-5409
91. Proctor AJ, Coombs LM, Cairns JP and Knowles MA (1991) Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogens 6 789-795
92. Ramchuuren N, Cooper K and Summerhayes IC (1995) Molecular events underlying schistosomiasis-related bladder cancer. International Journal of Cancer 62 237-244
93. Reznikoff CA, Belair CD, Yeager TR et al (1996) A molecular genetic model of human bladder cancer pathogenesis. Seminars in Oncology 5 571-584
94. Risch A, Wallace DMA, Bathers S and Sim E (1995) Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Human Molecular Genetics 4 231-236
95. Rosin MP, Cairns P, Epstein JI, Schoenberg MP and Sidransky D (1995) Partial allelotype of carcinoma in situ of the human bladder. Cancer Research 55 5213-5216
96. Ruppert JM, Tokino K and Sidransky D (1993) Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Research 53 5093-5095
97. Sandberg AA and Berger CS (1994) Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. Journal of Urology 151 545-560
98. Sarkis AS, Dalbagni G, Cordon-Cardo C et al (1993a) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. Journal of the National Cancer Institute 85 53-59
99. Sarkis AS, Zhang Z-F, Cordon-Cardo C et al (1993b) p53 nuclear overexpression and disease progression in Ta bladder carcinoma. International Journal of Oncology 3 355-360
100. Sarkis AS, Dalbagni G, Cordon-Cardo C et al (1994) Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. Journal of Urology 152 388-392
101. Sato K, Moriyama M, Mori S et al (1992) An immunohistologic evaluation of c-erbE-2 gene product in patients with urinary bladder carcinoma. Cancer 70 2493-2498
102. Sauter G, Moch H, Moore D et al (1993) Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Research 53 2199-2203
103. Schade ROK and Swinney J (1968) Pre-cancerous changes in bladder epithelium. Lancet ii 943-946
104. Schena M, Shalon D, Davis R and Brown P (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 467-470
105. Shapiro GI, Edwards CD, Kobzik L et al (1995) Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Research 55 505-509
106. Shaw ME and Knowles MA (1995) Deletion mapping of chromosome 11 in carcinoma of the bladder. Genes, Chromosomes and Cancer 13 1-8
107. Sidransky D, von Eschenbach A, Tsai YC et al (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252 706-709
108. Sidransky D, Frost P, von Eschenbach A, Oyasu R, Preisinger AC and Vogelstein B (1992) Clonal origin of bladder cancer. New England Journal of Medicine 326 737-740
109. Sigalas I, Calvert AH, Anderson JJ, Neal DE and Lunec J (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. 'Nature Medicine 2 912-917
110. Simoneau AR, Spruck CH III, Gonzalez-Zulueta M et al (1996) Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Research 56 5039-5043
111. Soini Y, Turpeenniemi-Hujanen T, Kamel D et al (1993) p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. British Journal of Cancer 68 1029-1035
112. Spruck CH III, Rideout WM III, Olumi AF et al (1993) Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Research 53 1162-1166
113. Spruck CH III, Gonzalez-Zulueta M, Shibata A et al (1994a) p16 gene in uncultured tumours. Nature 370 183-184
114. Spruck CH III, Ohneseit PF, Gonzalez,-Zulueta M et al (1994b) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Research 54 784-788
115. Takle LA and Knowles MA (1996) Deletion mapping implicates two tumour suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 12 1083-1087
116. Theodorescu D, Cornil I, Sheehan C, Man MS and Kerbel RS (1991) Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Research 51 4486-4491
117. Thompson TC, Truong LD, Timme TL et al (1993) Transgenic models for the study of prostate cancer. Cancer 71 1165-1171
118. Tsai YC, Nichols PW, Hiti AL et al (1990) Allelic losses of chromosomes 9, 11 and 17 in human bladder cancer. Cancer Research 50 44-47
119. Underwood M, Bartlett J, Reeves J, Gardiner S, Scott R and Cooke T (1995) C-erhB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Research 55 2422-2430
120. van Slegtenhorst M, de IIoogt T, Hermans C et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277 805-808
121. Velculescu VE, Zhang L, Vogelstein B and Kinzler KW (1995) Serial analysis of gene expression. Science 270 484-487
122. Voorter CEM, Ummelin MIJ, Ramaekers FSC and Hopman AHN (1996) Loss of chromosome 11 and 11P/Q imbalances in bladder cancer detected by fluorescence in situ hybridisation. International Journal of Cancer 65 301-307
123. Wagner HE, Steele G Jr and Summerhayes IC (1990) Preneoplastic lesions induced by myc and src oncogenes in reconstituted mouse bladder. Surgery 108 146-152
124. Wagner U, Sauter G, Moch H et al (1995) Patterns of p53, erbB-2 and EGF-r expression in premalignant lesions of the urinary bladder. Human Pathology 26 970-978
125. Waldman T, Lengauer C, Kinzler KW and Vogelstein B (1996) Uncoupling of S phase and mitosis by anticancer agents in cells lacking p21. Science 381 713-716
126. Warren W, Biggs PJ, El-Baz M, Ghoneim MA, Stratton MR and Venitt S (1995) Mutations in the p53 gene in sehistosomal bladder cancer: a study of 92 tumors from Egyptian patients and a comparison between spectra from sehistosomal and non-schistosomal urothelial tumors. Carcinogenesis 16 1181-1189
127. WHO (1985) The Control of Schintosomiasis. Report of a WHO Expert Committee. Geneva: World Health Organization
128. Williams B, Remington L, Albert D, Mukai S, Bronson R and Jacks T (1994) Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genetics 7 480-484
129. Williamson MP, Elder PA and Knowles MA (1994) The spectrum of TP53 mutations in bladder carcinoma. Genes, Chromosomes and Cancer 9 108-118
130. Williamson MP, Elder PA, Shaw ME, Devlin J and Knowles MA (1995) p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Human Molecular Genetics 4 1569-1577
131. Wu Q, Possati L, Montesi M et al (1996) Growth arrest and suppression of tumorigenicity of bladder carcinoma cell lines induced by the p16/CDKN2 (p16INK4A, MTS1) gene and other loci on chromosome 9. International journal of Cancer 65 840-846
132. Xu H-J, Cairns P, Hu S-X, Knowles MA and Benedict WF (1993) Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. International Journal of Cancer 53 781-784
133. Xu X, Stower MJ, Reid IN, Garner RC and Burns PA (1996) Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. Clinical Cancer Research 2 1795-1800
134. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O and Reznikoff C (1995) Increased p 16 levels correlate with pRB alterations in human urothelial cells. Cancer Research 55 493-497
135. Zhau HE, Zhang X, von Eschenbach AC, Scorsone K and Hung M-C (1990) Amplification and expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Molecular Carcinogenesis 3 254-257